# Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

> **NCT04766086** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 306 (actual)

## Conditions studied

- Group B Streptococcus Infections

## Interventions

- **BIOLOGICAL:** Multivalent Group B streptococcus vaccine
- **BIOLOGICAL:** Tetanus, diphtheria, and acellular pertussis vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04766086
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-12
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04766086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04766086, "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04766086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*